AIDS (acquired immune deficiency syndrome) is a condition that occurs in the most advanced stages of human immunodeficiency virus (HIV) infection. It may take many years for AIDS to develop following the initial HIV infection.
Although AIDS is primarily an immune system disorder, it also affects the nervous system and can lead to a wide range of severe neurological disorders.
The virus does not appear to directly invade nerve cells but it jeopardizes their health and function. The resulting inflammation may damage the brain and spinal cord and cause symptoms such as confusion and forgetfulness, behavioral changes, headaches, progressive weakness, and loss of sensation in the arms and legs. Cognitive motor impairment or damage to the peripheral nerves is also common. Research has shown that the HIV infection can significantly alter the size of certain brain structures involved in learning and information processing.
Other nervous system complications that occur as a result of the disease or the drugs used to treat it include pain, seizures, shingles, spinal cord problems, lack of coordination, difficult or painful swallowing, anxiety disorder, depression, fever, vision loss, gait disorders, destruction of brain tissue, and coma. These symptoms may be mild in the early stages of AIDS but can become progressively severe.
In the United States, neurological complications are seen in more than 50 percent of adults with AIDS. Nervous system complications in children may include developmental delays, loss of previously achieved milestones, brain lesions, nerve pain, smaller than normal skull size, slow growth, eye problems, and recurring bacterial infections.
AIDS-related disorders of the nervous system may be caused directly by the HIV virus, by certain cancers and opportunistic infections (illnesses caused by bacteria, fungi, and other viruses that would not otherwise affect people with healthy immune systems), or by toxic effects of the drugs used to treat symptoms. Other neuro-AIDS disorders of unknown origin may be influenced by but are not caused directly by the virus.
AIDS dementia complex (ADC), or HIV-associated dementia (HAD), occurs primarily in persons with more advanced HIV infection. Symptoms include encephalitis (inflammation of the brain), behavioral changes, and a gradual decline in cognitive function, including trouble with concentration, memory, and attention. Persons with ADC also show progressive slowing of motor function and loss of dexterity and coordination. When left untreated, ADC can be fatal. It is rare when anti-retroviral therapy is used. Milder cognitive complaints are common and are termed HIV-associated neurocognitive disorder (HAND). Neuropsychologic testing can reveal subtle deficits even in the absence of symptoms.
Central nervous system (CNS) lymphomas are cancerous tumors that either begin in the brain or result from a cancer that has spread from another site in the body. CNS lymphomas are almost always associated with the Epstein-Barr virus (a common human virus in the herpes family). Symptoms include headache, seizures, vision problems, dizziness, speech disturbance, paralysis, and mental deterioration. Individuals may develop one or more CNS lymphomas. Prognosis is poor due to advanced and increasing immunodeficiency, but is better with successful HIV therapy.
Cryptococcal meningitis is seen in about 10 percent of untreated individuals with AIDS and in other persons whose immune systems have been severely suppressed by disease or drugs. It is caused by the fungus Cryptococcus neoformans, which is commonly found in dirt and bird droppings. The fungus first invades the lungs and spreads to the covering of the brain and spinal cord, causing inflammation. Symptoms include fatigue, fever, headache, nausea, memory loss, confusion, drowsiness, and vomiting. If left untreated, patients with cryptococcal meningitis may lapse into a coma and die.
Cytomegalovirus (CMV) infections can occur concurrently with other infections. Symptoms of CMV encephalitis include weakness in the arms and legs, problems with hearing and balance, altered mental states, dementia, peripheral neuropathy, coma, and retinal disease that may lead to blindness. CMV infection of the spinal cord and nerves can result in weakness in the lower limbs and some paralysis, severe lower back pain, and loss of bladder function. It can also cause pneumonia and gastrointestinal disease. This is rarely seen in HIV-treated individuals since advanced immunity is required for CMV to emerge.
Herpes virus infections are often seen in people with AIDS. The herpes zoster virus, which causes chickenpox and shingles, can infect the brain and produce encephalitis and myelitis (inflammation of the spinal cord). It commonly produces shingles, which is an eruption of blisters and intense pain along an area of skin supplied by an infected nerve. In people exposed to herpes zoster, the virus can lay dormant in the nerve tissue for years until it is reactivated as shingles. This reactivation is common in persons with AIDS because of their weakened immune systems. Signs of shingles include painful blisters (like those seen in chickenpox), itching, tingling, and pain in the nerves.
People with AIDS may suffer from several different forms of neuropathy, or nerve pain, each strongly associated with a specific stage of active immunodeficiency disease. Peripheral neuropathy describes damage to the peripheral nerves, the vast communications network that transmits information between the brain and spinal cord to every other part of the body. Peripheral nerves also send sensory information back to the brain and spinal cord. HIV damages the nerve fibers that help conduct signals and can cause several different forms of neuropathy. Distal sensory polyneuropathy causes either a numbing feeling or a mild to painful burning or tingling sensation that normally begins in the legs and feet. These sensations may be particularly strong at night and may spread to the hands. Affected persons have a heightened sensitivity to pain, touch, or other stimuli. Onset usually occurs in the later stages of the HIV infection and may affect the majority of advanced-stage HIV patients.
Neurosyphilis, the result of an insufficiently treated syphilis infection, seems more frequent and more rapidly progressive in people with HIV infection. It may cause slow degeneration of the nerve cells and nerve fibers that carry sensory information to the brain. Symptoms, which may not appear for some decades after the initial infection and vary from person to person, include weakness, diminished reflexes, unsteady gait, progressive degeneration of the joints, loss of coordination, episodes of intense pain and disturbed sensation, personality changes, dementia, deafness, visual impairment, and impaired response to light. The disease is more frequent in men than in women. Onset is common during mid-life.
Progressive multifocal leukoencephalopathy (PML) primarily affects individuals with suppressed immune systems (including nearly 5 percent of people with AIDS). PML is caused by the JC virus, which travels to the brain, infects multiple sites, and destroys the cells that make myelin – the fatty protective covering for many of the body’s nerve and brain cells. Symptoms include various types of mental deterioration, vision loss, speech disturbances, ataxia (inability to coordinate movements), paralysis, brain lesions, and, ultimately, coma. Some individuals may also have compromised memory and cognition, and seizures may occur. PML is relentlessly progressive and death usually occurs within 6 months of initial symptoms. However, immune reconstitution with highly active antiretroviral therapy allows survival of more than half of HIV-associated PML cases in the current treatment era.
Psychological and neuropsychiatric disorders can occur in different phases of the HIV infection and AIDS and may take various and complex forms. Some illnesses, such as AIDS dementia complex, are caused directly by HIV infection of the brain, while other conditions may be triggered by the drugs used to combat the infection. Individuals may experience anxiety disorder, depressive disorders, increased thoughts of suicide, paranoia, dementia, delirium, cognitive impairment, confusion, hallucinations, behavioral abnormalities, malaise, and acute mania.
Toxoplasma encephalitis, also called cerebral toxoplasmosis, occurs in about 10 percent of untreated AIDS patients. It is caused by the parasite Toxoplasma gondii, which is carried by cats, birds, and other animals and can be found in soil contaminated by cat feces and sometimes in raw or undercooked meat. Once the parasite invades the immune system, it remains there; however, the immune system in a healthy person can fight off the parasite, preventing disease. Symptoms include encephalitis, fever, severe headache that does not respond to treatment, weakness on one side of the body, seizures, lethargy, increased confusion, vision problems, dizziness, problems with speaking and walking, vomiting, and personality changes. Not all patients show signs of the infection. Antibiotic therapy, if used early, will generally control the complication.
Vacuolar myelopathy causes the protective myelin sheath to pull away from nerve cells of the spinal cord, forming small holes called vacuoles in nerve fibers. Symptoms include weak and stiff legs and unsteadiness when walking. Walking becomes more difficult as the disease progresses and many patients eventually require a wheelchair. Some people also develop AIDS dementia. Vacuolar myelopathy may affect up to 30 percent of untreated adults with AIDS and its incidence may be even higher in HIV-infected children.
Based on the results of the individual's medical history and a general physical exam, the physician will conduct a thorough neurological exam to assess various functions: motor and sensory skills, nerve function, hearing and speech, vision, coordination and balance, mental status, and changes in mood or behavior. The physician may order laboratory tests and one or more of the following procedures to help diagnose neurological complications of AIDS.
Brain imaging can reveal signs of brain inflammation, tumors and CNS lymphomas, nerve damage, internal bleeding or hemorrhage, white matter irregularities, and other brain abnormalities. Several painless imaging procedures are used to help diagnose neurological complications of AIDS.
Electromyography, or EMG, is used to diagnose nerve and muscle dysfunction (such as neuropathy and nerve fiber damage caused by the HIV virus) and spinal cord disease. It records spontaneous muscle activity and muscle activity driven by the peripheral nerves.
Biopsy is the removal and examination of tissue from the body. A brain biopsy, which involves the surgical removal of a small piece of the brain or tumor, is used to determine intracranial disorders and tumor type. Unlike most other biopsies, it requires hospitalization. Muscle or nerve biopsies can help diagnose neuromuscular problems, while a brain biopsy can help diagnose a tumor, inflammation, or other irregularity.
Cerebrospinal fluid analysis can detect any bleeding or brain hemorrhage, infections of the brain or spinal cord (such as neurosyphilis), and any harmful buildup of fluid. It can also be used to sample viruses that may be affecting the brain. A sample of the fluid is removed by needle, under local anesthesia, and studied to detect any irregularities.
No single treatment can cure the neurological complications of AIDS. Some disorders require aggressive therapy while others are treated symptomatically.
Neuropathic pain is often difficult to control. Medicines range from analgesics sold over the counter to antiepileptic drugs, opiates, and some classes of antidepressants. Inflamed tissue can press on nerves, causing pain. Inflammatory and autoimmune conditions leading to neuropathy may be treated with corticosteroids, and procedures such as plasmapheresis (or plasma exchange) can clear the blood of harmful substances that cause inflammation.
Treatment options for AIDS- and HIV-related neuropsychiatric or psychotic disorders include antidepressants and anticonvulsants. Psychostimulants may also improve depressive symptoms and combat lethargy. Antidementia drugs may relieve confusion and slow mental decline, and benzodiazepines may be prescribed to treat anxiety. Psychotherapy may also help some individuals.
Aggressive antiretroviral therapy is used to treat AIDS dementia complex, vacuolar myopathy, progressive multifocal leukoencephalopathy, and cytomegalovirus encephalitis. HAART, or highly active antiretroviral therapy, combines at least three drugs to reduce the amount of virus circulating in the blood and may also delay the start of some infections.
Other neuro-AIDS treatment options include physical therapy and rehabilitation, radiation therapy and/or chemotherapy to kill or shrink cancerous brain tumors that may be caused by the HIV virus, antifungal or antimalarial drugs to combat certain bacterial infections associated with the disorder, and penicillin to treat neurosyphilis.
Within the Federal government, the National Institute of Neurological Disorders and Stroke (NINDS), one part of the National Institutes of Health (NIH), supports research on the neurological consequences of AIDS. The NINDS works closely with its sister agency, the National Institute of Allergy and Infectious Diseases (NIAID), which has primary responsibility for research related to HIV and AIDS.
Several NINDS-funded projects are studying the role of virally infected brain macrophages (cells that normally work to protect against infection) in causing disease in the central nervous system of adult macaques. The focus of these projects includes gene analyses and the study of key neuroimmune regulatory molecules that are turned on in the brain during the course of viral infection at levels that have been shown to be toxic.
Several animal-based models of HIV (including mouse, rat, and simian models) are used by scientists to study disease mechanisms and the course of AIDS, and NINDS grantees are working to develop new models of HIV. Several projects rely on a mouse model of severe combined immunodeficiency (a group of inherited disorders that are characterized by a lack of or severe defect in cells responsible for protecting the immune system). This model allows researchers to transplant developing human brain tissue from culture into the brains of the mice to monitor and assess neurologic damage caused by HIV infection. Other studies use mice bred to carry symptoms of HIV, and NINDS grantees are using these animals to see if the brain can function as a sanctuary for HIV-infected cells that can migrate to and infect peripheral lymph tissue.
The NINDS also supports research into the mechanisms of neurological illnesses related to immunodeficiency in AIDS patients. Several different investigators are studying the JC virus, which can reproduce in the brains of immunosuppressed patients and cause PML, and one study identified a novel receptor for the JC virus. Other studies of infectious agents include an investigation of the interaction of the fungal agent Cryptococcus with the blood vessels of the brain, and an analysis of neurosyphilis in people with AIDS. Scientists are also studying the effect of neurotoxic proteins and antiviral therapies directly on nerve cells as the cause for distal sensory peripheral neuropathy.
Several researchers are studying AIDS dementia and cognitive changes in HIV. NINDS-sponsored scientists are using fMRI and MRS to assess brain function and any behavioral deficits in HIV-affected individuals. Investigators hope to better understand how progressive neuronal cell death contributes to cognitive dysfunction and AIDS dementia. The National NeuroAIDS Tissue Consortium, a project supported jointly by the NINDS and its sister agency, the National Institute of Mental Health, is collecting tissues from people with AIDS who have suffered from dementia and other neurological complications of HIV infection for distribution to researchers around the globe.
The Neurological AIDS Research Consortium was established by the NINDS in 1993 to design and conduct clinical trials on HIV-associated neurologic disease. To date, the Consortium has supported studies of neurological function in advanced AIDS and the treatment of HIV-associated peripheral neuropathy, PML, and CMV infection. Current studies are optimizing therapy for painful neuropathy using methadone and duloxetine. Recent studies evaluated minocycline for dementia treatment and are studying the effects of salvage HAART (using drug therapies to treat HIV strains that have become resistant to drug combination therapy0 in the nervous system.
For more information on neurological disorders or research programs funded by the National Institute of Neurological Disorders and Stroke, contact the Institute's Brain Resources and Information Network (BRAIN) at:
P.O. Box 5801
Bethesda, MD 20824
Information also is available from the following organizations:
Elizabeth Glaser Pediatric AIDS Foundation
1140 Connecticut Avenue, NW
Washington, DC 20036
Tel: 202-296-9165 888-499-HOPE (-4673)
amfAR, The Foundation for AIDS Research
120 Wall Street
New York, NY 10005-3908
National Association of People with AIDS
8401 Colesville Road
Silver Spring, MD 20910
Tel: 240-247-0880 or 866-846-9366
National NeuroAIDS Tissue Consortium
401 N. Washington Street
Rockville, MD 20850
Tel: 866-668-2272 301-251-1161 ext. 186
National Prevention Information Network
Centers for Disease Control and Prevention, DHHS
P.O. Box 6003
Rockville, MD 20849-6003
Tel: 301-562-1098 800-458-5231
NIAID Office of Communications and Government Relations
National Institutes of Health, DHHS
5601 Fishers Lane, MSC 9806
Bethesda, MD 20892
AIDSInfo (AIDS Information Service)
P.O. Box 4780
Rockville, MD 20849-6303
Tel: 800-HIV-0440 (448-0440) TTY: 888-480-3739
Neurologic AIDS Research Consortium
Department of Neurology Washington School of Medicine Campus Box 8111
660 S. Euclid Avenue
St. Louis, MO 63110
Neurologic AIDS Research Consortium
Department of Neurology Washington School of Medicine Campus Box 8111
660 S. Euclid Avenue
St. Louis, MO 63110
"Neurological Complications of AIDSFact Sheet", NINDS, Publication date January 2006.
NIH Publication No. 06-5319
Publicaciones en Español
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892
NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.
All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.
Last Modified November 2, 2015